Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | growth differentiation factor 8 |
Clinical data | |
Other names | REGN1033 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6374H9884N1696O2018S46 |
Molar mass | 144037.80 g·mol−1 |
Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.
This drug was developed by Regeneron Pharmaceuticals, Inc.[2]